BioArctic, Mesenkia sign research collaboration on glioblastoma antibody delivery approach

Reuters2026/08/19 09:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioArctic signed a research collaboration with Mesenkia to develop an antibody-based treatment approach for glioblastoma.
Project combines BioArctic’s BrainTransporter technology with a Mesenkia antibody from its KITAIbodies platform targeting HVEM on tumor cells.
BioArctic will create the drug candidate; the partners plan preclinical studies to validate the concept before deciding next steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 202608190515BITN____UKPR__EN_20260819-BIT-9481-0) on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioArctic, Mesenkia sign research collaboration on glioblastoma antibody delivery approach

You may also like

Crypto prices